Follow Us
© 2026 Arizent. All rights reserved.
The $56,000 annual price for Biogen’s recently approved Alzheimer’s therapy is drawing increasing criticism ahead of a decision by the U.S. government on reimbursement policies for the medication.
The Employers’ Prescription for Affordable Drugs, a coalition of health-care purchasers, said in a letter to congressional leaders on Monday that taxpayers and employers will have to pay billions of dollars for the drug, called Aduhelm, without knowing whether it works.
For reprint and licensing requests for this article, click here.
As healthcare expenses approach double-digit increases, employers are looking for savings in waste, care delivery, and plan administration before cutting benefits.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
As the scope of gene therapy grows, understanding their impact and cost can help organizations decide how to cover them through their healthcare plans.
Through digital health company eMed, Brady, its chief wellness officer, and CEO Linda Yaccarino designed a fixed-cost program for GLP-1 medication and clinical services.
The U.S. agreed to exempt U.K. pharmaceutical products from tariffs.
